Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase...

Prof Jorge Cortes - Augusta University, Augusta, USA

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute...

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory...

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

$AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )$

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

$CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )$

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Patient reported outcomes for the CANDOR trial for multiple myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

Patient reported outcomes for the CANDOR trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple...

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients...

Prof Lionel Ades - Hôpital Saint-Louis, Paris, France

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML ( Prof Lionel Ades - Hôpital Saint-Louis, Paris, France )

Timing of response to venetoclax combination treatment in older patients with...

Dr Brian Jonas - University of California Davis Comprehensive Cancer Center...

Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia ( Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sacramento, USA )

Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

$Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )$

More from ecancer